Zealand Pharma A/SZEAL.CO
What Zealand Pharma A/S does.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Revenue and profit, by fiscal year.
| Fiscal year | 2018 | 2019 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | DKK 38.0M | DKK 41.3M | DKK 104.0M | DKK 342.8M | DKK 62.7M | DKK 9.2B |
| Net income | DKK 581.3M | -DKK 571.5M | -DKK 1.2B | -DKK 703.7M | -DKK 1.1B | DKK 6.5B |
| Free cash flow | -DKK 465.5M | -DKK 430.5M | -DKK 954.0M | -DKK 436.9M | -DKK 940.9M | DKK 6.5B |
More on ZEAL.CO.
- Zealand Pharma A/S summary
- Zealand Pharma A/S financial statements
- Zealand Pharma A/S key metrics
- Zealand Pharma A/S health scores
- Zealand Pharma A/S valuation
- Zealand Pharma A/S dividends
- Zealand Pharma A/S peers
- Zealand Pharma A/S annual reports
Figures from Zealand Pharma A/S's annual reports (ESEF, via filings.xbrl.org) and Yahoo Finance, standardised automatically; prices are end-of-day closes. Not financial advice.